Cytokinetics to focus on heart disease drug after ALS trial failure
Cytokinetics Inc said on Friday it would focus on its heart disease treatment after its amyotrophic lateral sclerosis (ALS) drug failed a late-stage study.
Source: reuters.com
Page 30 - Robert Blum News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Robert Blum. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Robert Blum Today - Breaking & Trending Today
Cytokinetics Stops ALS Program After Analysis Finds No Evidence of Effect
Cytokinetics drug reldesemtiv has failed a pivotal clinical trial in amyotrophic lateral sclerosis. The small molecule had previously failed in Phase 2, but the biotech believed adjustments could lead to better results in Phase 3.
Source: medcitynews.com
Acasti Pharma Inc. Announces the Resignation of a Director
/PRNewswire/ -- Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ: ACST) a late-stage, specialty pharma company advancing three clinical stage drug...
Source: prnewswire.com
Gamida Cell Ltd. (NASDAQ:GMDA) Q4 2023 Earnings Call Transcript
Operator: Ladies and gentlemen, thank you for standing by. Welcome to the Gamida Cell's Conference Call for the Full Year 2022 Financial Results.
Source: insidermonkey.com